Goldman Sachs analyst Paul Choi initiated coverage of Xenon Pharmaceuticals with a Buy rating and $60 price target. The company offers "innovation and blockbuster potential in an overlooked neuro category," Choi tells investors in a research note. The analyst sees near-to-medium term stock performance driven primarily by updates on XEN1101 in focal onset seizure, which he views as a "largely de-risked" lead indication.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on XENE:
- Xenon Pharmaceuticals initiated with an Outperform at Cowen on XEN1101 optimism
- Xenon Pharmaceuticals initiated with an Outperform at Cowen
- Xenon Pharmaceuticals Provides Updates on Proprietary Neurology Pipeline Programs at the Annual Meeting of the American Epilepsy Society (AES 2022)
- Xenon Pharmaceuticals provides updates on neurology programs at AES 2022
- Xenon Pharmaceuticals to Present at the Bank of America Securities Biotech SMID Cap Conference 2022